Want to see SEELQ full AI Analyst Report?
Top Page
Seelos Therapeutics
(OTC:SEELQ)
Select Model
Select Model
Rating:30Underperform
Price Target:―
Action:N/A
Date:11/14/24
Seelos Therapeutics faces substantial financial and operational challenges, reflected in poor financial and technical scores. The low valuation score suggests potential undervaluation, but risks related to financial health and lack of guidance from the earnings call weigh heavily on the outlook.
Positive Factors
Pipeline Potential
Seelos' focus on CNS disorders and rare diseases positions it well in niche markets with high unmet needs, potentially leading to successful drug approvals and partnerships.
Negative Factors
Negative Stockholders' Equity
Negative equity suggests liabilities exceed assets, posing solvency risks and necessitating financial restructuring to ensure long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline Potential
Seelos' focus on CNS disorders and rare diseases positions it well in niche markets with high unmet needs, potentially leading to successful drug approvals and partnerships.
Read all positive factors
Seelos Therapeutics (SEELQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$112.00
Dividend YieldN/A
Average Volume (3M)423.00
Price to Earnings (P/E)―
Beta (1Y)26.35
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,124,121
10 Day Avg. Volume423
30 Day Avg. Volume423
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap101.47K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Seelos Therapeutics Business Overview & Revenue Model
Company Description
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfoli...
How the Company Makes Money
Seelos Therapeutics generates revenue primarily through partnerships, collaborations, and potential licensing agreements related to its pharmaceutical development programs. As a clinical-stage company, it does not yet have products on the market, ...
Seelos Therapeutics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | ― | ― | ― | ― | ― |
| Gross Profit | 2.20M | ― | ― | ― | 151.00K |
| EBITDA | -37.75M | -73.47M | -64.45M | -18.94M | -51.23M |
| Net Income | -37.88M | -73.53M | -66.05M | -19.10M | -51.26M |
Balance Sheet | |||||
| Total Assets | 5.42M | 22.75M | 83.50M | 17.49M | 11.10M |
| Cash, Cash Equivalents and Short-Term Investments | ― | ― | ― | ― | ― |
| Total Debt | 14.23M | 20.12M | 18.96M | 9.72M | 0.00 |
| Total Liabilities | 38.93M | 33.36M | 26.18M | 14.92M | 11.10M |
| Stockholders Equity | ― | ― | ― | ― | ― |
Cash Flow | |||||
| Free Cash Flow | -23.91M | -61.60M | -48.99M | -20.91M | -19.30M |
| Operating Cash Flow | -23.91M | -61.60M | -48.99M | -20.91M | -19.30M |
| Investing Cash Flow | ― | ― | ― | ― | ― |
| Financing Cash Flow | ― | ― | ― | ― | ― |
Seelos Therapeutics Technical Analysis
Neutral
0.18
Price Trends
Market Momentum
>-0.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEELQ, the sentiment is Neutral. The current price of 0.18 is below the 20-day moving average (MA) of 0.18, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of 0.00 is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SEELQ.
Seelos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $6.30M | -0.07 | -134.03% | ― | ― | 93.96% | |
47 Neutral | $4.87M | -0.28 | -166.67% | ― | ― | 88.77% | |
44 Neutral | $6.22M | -0.08 | -168.05% | ― | ― | 87.05% | |
41 Neutral | $1.06M | ― | -26.63% | ― | 30.12% | -165.46% | |
30 Underperform | $112.00 | ― | ― | ― | ― | ― |
* Healthcare Sector Average
SEELQ
Seelos Therapeutics
0.18
0.00
0.00%
SCNI
Scinai Immunotherapeutics
1.86
-13.34
-87.76%
ENVB
Enveric Biosciences
1.39
-9.40
-87.12%
GRI
GRI Bio
2.88
-40.80
-93.41%
DRMA
Dermata Therapeutics
1.21
-4.05
-77.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.